Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study.
Rodrigues JM, Hollander P, Schmidt L, Gkika E, Razmara M, Kumar D, Geisler C, Grønbæk K, Eskelund CW, Räty R, Kolstad A, Sundström C, Glimelius I, Porwit A, Jerkeman M, Ek S. Rodrigues JM, et al. Among authors: raty r. Haematologica. 2024 Apr 1;109(4):1171-1183. doi: 10.3324/haematol.2023.283352. Haematologica. 2024. PMID: 37646663 Free PMC article.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Among authors: raty r. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Gerdtsson AS, Matos Rodrigues J, Eskelund CW, Husby S, Grønbæk K, Räty R, Kolstad A, Geisler C, Porwit A, Jerkeman M, Ek S. Gerdtsson AS, et al. Among authors: raty r. Haematologica. 2023 Apr 1;108(4):1092-1104. doi: 10.3324/haematol.2022.281420. Haematologica. 2023. PMID: 36519324 Free PMC article.
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
Husby S, Bæch-Laursen C, Eskelund CW, Favero F, Jespersen JS, Hutchings M, Pedersen LB, Niemann CU, Weischenfeldt J, Räty R, Larsen TS, Kolstad A, Jerkeman M, Grønbæk K. Husby S, et al. Among authors: raty r. Leukemia. 2022 Dec;36(12):2912-2916. doi: 10.1038/s41375-022-01725-8. Epub 2022 Oct 23. Leukemia. 2022. PMID: 36274067 No abstract available.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen A, Sinisalo M, Huhtala H, Rimpiläinen J, Rintala H, Sankelo M, Koivunen E, Silvennoinen R, Räty R, Ruutu T, Volin L, Porkka K, Jantunen E, Nousiainen T, Kuittinen T, Penttilä K, Pyörälä M, Säily M, Koistinen P, Kauppila M, Itälä-Remes M, Ollikainen H, Rauhala A, Kairisto V, Pelliniemi TT, Elonen E; Finnish Leukemia Group. Kolonen A, et al. Among authors: raty r. Eur J Haematol. 2022 Sep;109(3):257-270. doi: 10.1111/ejh.13805. Epub 2022 Jun 14. Eur J Haematol. 2022. PMID: 35634931 Clinical Trial.
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN, Als-Nielsen B, Bacon C, Bertasiute R, Duarte X, Escherich G, Helgadottir EA, Johannsdottir IR, Jónsson ÓG, Kozlowski P, Langenskjöld C, Lepik K, Niinimäki R, Overgaard UM, Punab M, Räty R, Segers H, van der Sluis I, Smith OP, Strullu M, Vaitkevičienė G, Wik HS, Heyman M, Schmiegelow K. Toksvang LN, et al. Among authors: raty r. BMC Cancer. 2022 May 2;22(1):483. doi: 10.1186/s12885-022-09522-3. BMC Cancer. 2022. PMID: 35501736 Free PMC article.
Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Grønbæk K. Dahl M, et al. Among authors: raty r. Leukemia. 2022 Apr;36(4):1198. doi: 10.1038/s41375-022-01526-z. Leukemia. 2022. PMID: 35181760 No abstract available.
75 results